Faricimab Injection [Vabysmo]
Approved
Faricimab Injection [Vabysmo] is one of 9 therapeutic programs targeting Histoplasmosis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
15 competitors in Histoplasmosis
#DrugCompanyPhaseTrials
1Sporanox
SSebela Pharmaceuticals Development LLC
Phase 3
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Visudyne
BBausch Health Americas, Inc.
Phase 2
Faricimab Injection [Vabysmo]
CCincinnati Eye Institute, Southwest Ohio
Approved
Eylea
RegeneronPhase 1
Lucentis
RochePhase 1
Macugen
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Histoplasmosis1 trial
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Approved[1]